Why Biosimilars can Never be Identical to Originators-and Why they Don't Need to be

Reinke, T.

Managed Care 28(1): 10-11

2019


ISSN/ISBN: 1062-3388
PMID: 30883316
Document Number: 697794
The FDA's approval criteria require a biosimilar to be highly similar to its original biologic and show "no clinically meaningful differences." But mere similarity is not close enough for many clinicians and some patients; it makes biosimilars seem riskier than the original biologics.

Document emailed within 1 workday
Secure & encrypted payments